Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | HTR2B | P41595 | 4/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16312420 | 0.88 | NOS3 (0.41) | HRH3HRH4HTR2AHTR2CHTR2B | |
| SCHEMBL31157575 | 0.85 | HRH4 (0.47) | HRH3HRH4CYP1A2CYP2D6 | |
| SCHEMBL12847647 | 0.81 | HTR2A (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL3379212 | 0.79 | — | — | |
| SCHEMBL3381880 | 0.79 | — | — | |
| SCHEMBL12790387 | 0.79 | HTR3E (0.32) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| Histamine SCHEMBL27890671 | 0.78 | HRH4 (0.41) | HRH3HRH4 | |
| SCHEMBL8300505 | 0.77 | LMNA (0.32) | — | |
| SCHEMBL326787 | 0.76 | — | — | |
| SCHEMBL5322896 | 0.75 | HRH4 (0.32) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1203586-A2 | Compositions comprising a mast cell degranulation-blocking agent for treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin. | KOS PHARMACEUTICALS, INC. (US) | 2002-05-08 | — | — | EP | claimed |
| US-5648355-A | MAST CELL DEGRANULATION-BLOCK AGENTS | KOS PHARMACEUTICAL, INC. (US) | 1997-07-15 | — | — | US | claimed |
| EP-0748217-A1 | COMPOSITIONS COMPRISING A MAST CELL DEGRANULATION-BLOCKING AGENT FOR TREATMENT OF ENDOGENOUS, PAINFUL GASTROINTESTINAL CONDITIONS OF NON-INFLAMMATORY, NON-ULCERATIVE ORIGIN | KOS PHARMACEUTICALS, INC. (US) | 1996-12-18 | — | — | EP | claimed |
| WO-1995021611-A2 | COMPOSITIONS COMPRISING A MAST CELL DEGRANULATION-BLOCKING AGENT FOR TREATMENT OF ENDOGENOUS, PAINFUL GASTROINTESTINAL CONDITIONS OF NON-INFLAMMATORY, NON-ULCERATIVE ORIGIN | KOS PHARMACEUTICALS, INC. (US) | 1995-08-17 | — | — | WO | claimed |
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-14 | — | — | US | disclosed |
| US-9006487-B2 | Amine-containing lipids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| EP-1203586-A2 | Compositions comprising a mast cell degranulation-blocking agent for treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin. | KOS PHARMACEUTICALS, INC. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6028095-A | Treatment of inflammatory bowel disease using histamine H3 -receptor agonists | WARNER-LAMBERT COMPANY (US) | 2000-02-22 | — | — | US | disclosed |
| US-5648355-A | MAST CELL DEGRANULATION-BLOCK AGENTS | KOS PHARMACEUTICAL, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0748217-A1 | COMPOSITIONS COMPRISING A MAST CELL DEGRANULATION-BLOCKING AGENT FOR TREATMENT OF ENDOGENOUS, PAINFUL GASTROINTESTINAL CONDITIONS OF NON-INFLAMMATORY, NON-ULCERATIVE ORIGIN | KOS PHARMACEUTICALS, INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995021611-A2 | COMPOSITIONS COMPRISING A MAST CELL DEGRANULATION-BLOCKING AGENT FOR TREATMENT OF ENDOGENOUS, PAINFUL GASTROINTESTINAL CONDITIONS OF NON-INFLAMMATORY, NON-ULCERATIVE ORIGIN | KOS PHARMACEUTICALS, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0056025-A1 | HEME CONCENTRATE AND METHOD FOR THE PREPARATION THEREOF. | LINDROOS PAUL GORAN SIGVARD | 1982-07-21 | — | — | EP | disclosed |
| WO-1981002834-A1 | HEME CONCENTRATE AND METHOD FOR THE PREPARATION THEREOF | LINDROOS P | 1981-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | HRH3 4238/4885TAAR1 3752/4885HRH4 4303/4885 |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | HRH3 914/4885TAAR1 547/4885HRH4 2136/4885 |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | PHOSPHO1, CHMP4B, SGMS1 | HRH3 1075/4885TAAR1 549/4885HRH4 1681/4885 |
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | PHOSPHO1, CHMP4B, SGMS1 | HRH3 1075/4885TAAR1 549/4885HRH4 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.